|1.||Hamilton, Alan: 9 articles (10/2015 - 01/2014)|
|2.||Korducki, Lawrence: 9 articles (10/2015 - 01/2014)|
|3.||Abrahams, Roger: 5 articles (10/2015 - 01/2014)|
|4.||Grönke, Lars: 5 articles (10/2015 - 04/2015)|
|5.||Fležar, Matjaž: 5 articles (06/2015 - 01/2015)|
|6.||Tetzlaff, Kay: 4 articles (10/2015 - 04/2015)|
|7.||Bjermer, Leif: 4 articles (10/2015 - 04/2015)|
|8.||Ferguson, Gary T: 4 articles (10/2015 - 01/2014)|
|9.||McGarvey, Lorcan: 3 articles (10/2015 - 04/2015)|
|10.||Waitere-Wijker, Stella: 3 articles (09/2015 - 04/2015)|
|1.||Chronic Obstructive Pulmonary Disease (COPD)
01/01/2014 - "Two replicate, randomized, double-blind, placebo-controlled, parallel-group, Phase III trials were performed as part of a comprehensive clinical program to investigate the long-term safety and efficacy of olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) receiving usual-care background therapy. "
10/01/2015 - "This analysis of four randomized, double-blind, placebo-controlled, parallel-group, phase III studies (1222.11, NCT00782210; 1222.12, NCT00782509; 1222.13, NCT00793624; 1222.14, NCT00796653) evaluated the long-term safety of olodaterol once daily (QD) in a large cohort of patients with moderate to very severe (Global initiative for chronic Obstructive Lung Disease 2-4) chronic obstructive pulmonary disease (COPD). "
05/01/2015 - "This Phase II, multicentre, randomised, double-blind, placebo-controlled, parallel-group, dose-finding study evaluated four doses of once-daily olodaterol over 4 weeks in patients with chronic obstructive pulmonary disease (COPD), based on efficacy, safety and pharmacokinetic parameters. "
05/01/2015 - "A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease."
05/01/2015 - "This randomised, double-blind, four-way, crossover, Phase II study compared the 24-h forced expiratory volume in 1 s (FEV1) profile of alternative dosing frequencies of two total daily doses of olodaterol (5 and 10 μg) in patients with chronic obstructive pulmonary disease (COPD). "
|2.||Asthma (Bronchial Asthma)
02/01/2014 - "The novel once-daily β₂-agonist bronchodilator drug olodaterol has recently been shown to be effective in patients with allergic asthma for >24 hours. "
01/01/2015 - "Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study."
01/01/2015 - "A Phase II, multicentre, randomised, double-blind, placebo-controlled, crossover trial comparing the 24-h forced expiratory volume in 1 s (FEV1) time profile after 3 weeks' treatment with once-daily (QD) or twice-daily (BID) olodaterol (at the same total daily dose) versus placebo delivered via Respimat® in patients with moderate to severe asthma. "
01/01/2015 - "Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma."
01/01/2015 - "Olodaterol is a novel, inhaled long-acting β2-agonist (LABA) with >24-hour duration of action investigated in asthma and chronic obstructive pulmonary disease. "
07/01/2015 - "The aim of our study was to determine the efficacy of the long-acting β2 -adrenoceptor agonist olodaterol to inhibit pulmonary inflammation and to elucidate mechanism(s) underlying its anti-inflammatory actions. "
07/01/2015 - "The long-acting β2 -adrenoceptor agonist olodaterol attenuated pulmonary inflammation through mechanisms that are separate from direct inhibition of bronchoconstriction. "
07/01/2015 - "Olodaterol dose-dependently attenuated cell influx and pro-inflammatory mediator release in murine and guinea pig models of pulmonary inflammation. "
07/01/2015 - "The long-acting β2 -adrenoceptor agonist olodaterol attenuates pulmonary inflammation."
07/01/2015 - "Olodaterol was tested in murine and guinea pig models of cigarette smoke- and LPS-induced lung inflammation. "
01/01/2015 - "The aim of our study was to test the efficacy of the long-acting β2-AR agonist olodaterol with regard to its antitussive property in a pre-clinical model of citric acid-induced cough in guinea pigs and to compare the results to different clinically relevant β2-AR agonists. "
01/01/2015 - "Olodaterol dose-dependently inhibited the number of cough events in naïve and even more potently and with a greater maximal efficacy in ovalbumin-sensitized guinea pigs (p < 0.01). "
01/01/2015 - "In conclusion, olodaterol, at doses eliciting bronchodilation, showed antitussive properties in a model of citric acid-induced cough in naïve and ovalbumin-sensitized guinea pigs. "
01/01/2015 - "Olodaterol attenuates citric acid-induced cough in naïve and ovalbumin-sensitized and challenged guinea pigs."
|5.||Dyspnea (Shortness of Breath)
|2.||Citric Acid (Citrate)
|5.||5- (2- (5,6- diethylindan- 2- ylamino)- 1- hydroxyethyl)- 8- hydroxy- 1H- quinolin- 2- one
|6.||Adrenal Cortex Hormones (Corticosteroids)
|7.||maleic acid (maleate)
|8.||4- (2- ((6- ((2- (((2,6- dichlorophenyl)methyl)oxy)ethyl)oxy)hexyl)amino)- 1- hydroxyethyl)- 2- (hydroxymethyl)phenol
|9.||Bronchodilator Agents (Bronchodilators)
|1.||Nebulizers and Vaporizers (Inhaler)